Ken Griffin Satsuma Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

2 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.61 - $5.06 $5,490 - $45,540
-9,000 Reduced 80.36%
2,200 $1,000
Q3 2022

Nov 14, 2022
BUY
$4.19 - $7.95 $46,928 - $89,040
11,200 New
11,200 $67,000

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email